CompletedPhase 2NCT00747487
Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy
Studying Hereditary optic neuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Santhera Pharmaceuticals
- Principal Investigator
- Prof Patrick F Chinnery, MDClinical Research Facility, 4th Floor Leazes Wing, Royal Victoria Infirmary
- Intervention
- Idebenone(drug)
- Enrollment
- 85 enrolled
- Eligibility
- 14-65 years · All sexes
- Timeline
- 2007 – 2010
Study locations (3)
- Unité de recherche clinique Ophtalmologie- Hopital Notre-Dame, Montreal, Quebec, Canada
- Klinikum der Universität München - Grosshadern, Neurologische Klinik und Poliklinik, Munich, Germany
- Clinical Research Facility, 4th Floor Leazes Wing, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00747487 on ClinicalTrials.govOther trials for Hereditary optic neuropathy
Additional recruiting or active studies for the same condition.